HUTCHMED Completes Enrollment for Phase II Registration Trial of Fanregratinib in FGFR2-Fusion Cholangiocarcinoma
核心洞察
HUTCHMED has completed enrollment of 87 patients in a Phase II registration trial evaluating fanregratinib (搜索) for intrahepatic cholangiocarcinoma (搜索) patients with FGFR2 fusion/rearrangement.
The single-arm, multi-center study will assess efficacy and safety metrics including objective response rate as the primary endpoint, with topline results expected by late 2025.
The trial targets a significant unmet need, as FGFR2 fusion occurs in 10-15% of IHCC patients, with China seeing over 60,000 new IHCC cases in 2015 and incidence rising 9.2% annually.
HUTCHMED has reached a significant milestone in its development of fanregratinib (搜索) (HMPL-453), completing enrollment for a Phase II registration trial targeting intrahepatic cholangiocarcinoma (搜索) (IHCC) patients with FGFR2 fusion/rearrangement. The study, which began dosing patients in March 2023, has successfully enrolled 87 participants in its registration phase.
Trial Design and Objectives
The single-arm, multi-center, open-label study aims to evaluate fanregratinib (搜索)'s efficacy, safety, and pharmacokinetic profile in advanced IHCC patients. The trial's primary endpoint focuses on objective response rate (ORR), while secondary endpoints encompass progression-free survival (PFS), disease control rate (DCR), duration of response (DoR), and overall survival (OS).
Therapeutic Mechanism and Market Need
Fanregratinib (搜索) is a novel, highly selective inhibitor targeting FGFR (搜索) 1, 2, and 3. The drug's development addresses a critical therapeutic need, as aberrant FGFR signaling has been identified as a key driver of tumor growth and angiogenesis promotion. The compound's selective targeting mechanism may offer new hope for IHCC patients with specific genetic alterations.
Disease Burden and Target Population
The development carries particular significance in China, where IHCC presents a growing health challenge. Recent epidemiological data reveals that approximately 61,900 new IHCC cases were diagnosed in China in 2015, with incidence rates climbing by 9.2% annually between 2006 and 2015. Importantly, FGFR2 fusion occurs in 10-15% of IHCC patients, defining a specific subset that could potentially benefit from targeted therapy.
Development Timeline and Next Steps
HUTCHMED anticipates announcing topline results from the study around the end of 2025. Positive outcomes could pave the way for a New Drug Application submission to China's National Medical Products Administration (NMPA). The company currently maintains worldwide rights to fanregratinib (搜索), positioning it for potential global development.
Strategic Implications
This development represents a significant step in HUTCHMED's oncology pipeline, particularly in precision medicine targeting specific genetic alterations. Success in this trial could establish fanregratinib (搜索) as a valuable treatment option for a well-defined patient population with limited current therapeutic options.